Participation of protein kinase C in desensitization to bradykinin and to carbachol in MDCK cells.
To explore the possibility that protein kinase C (PKC) participates in desensitization to Ca(2+)-mobilizing hormones in MDCK cells, we measured intracellular free Ca2+ concentration ([Ca2+]i) using fura-2 and video microscopy. We first examined the response of MDCK cells grown on plastic dishes. Exposure of cells to bradykinin (BK) or to carbachol, followed by reexposure after washing off the hormone, revealed two features of hormone desensitization. First, the initial hormone-induced peak response of [Ca2+]i was transitory; [Ca2+]i returned to control levels despite continued presence of hormone. Second, cells remained refractory to hormone rechallenge for 5 min after washing off hormone; [Ca2+]i response on re-exposure was reduced 70% compared with initial hormone-stimulated peak. Subsequent experiments demonstrated involvement of PKC in both desensitization processes. Pretreatment with the phorbol ester, phorbol 12-myristate 13-acetate, significantly blunted initial response to BK and to carbachol by 70 and 86%, respectively. When hormone-stimulated C kinase activity was enhanced with the diglyceride lipase inhibitor, RG 80267, BK- and carbachol-induced increases in [Ca2+]i were blunted 50%. Pretreatment with sphingosine, an inhibitor of PKC, resulted in an amplification of initial hormone-stimulated increase in [Ca2+]i and restored the response to rechallenge. To examine the possible interaction between BK and carbachol,both of which use PKC to induce desensitization, we measured [Ca2+]i in cells grown as monolayers on permeable, collagen-coated supports. Both carbachol and BK induced desensitization to the other hormone (heterologous desensitization)provided that the two hormones were applied to the same side of the polarized monolayer (apical).(ABSTRACT TRUNCATED AT 250 WORDS)
Luo
H
H
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032.
Lindeman
R P
RP
Chase
H S
HS
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000818:Animals; D001920:Bradykinin / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D002217:Carbachol / Q000494:pharmacology*; D002460:Cell Line; D002462:Cell Membrane / Q000187:drug effects / Q000502:physiology; D004285:Dogs; D004848:Epithelium / Q000187:drug effects / Q000502:physiology; D007546:Isoquinolines / Q000494:pharmacology; D007668:Kidney; D007700:Kinetics; D008856:Microscopy, Fluorescence; D010879:Piperazines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000502:physiology; D013110:Sphingosine / Q000494:pharmacology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
D007546:Isoquinolines; D010879:Piperazines; D011956:Receptors, Cell Surface; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D002217:Carbachol; D011493:Protein Kinase C; D013110:Sphingosine; D013755:Tetradecanoylphorbol Acetate; D001920:Bradykinin; D002118:Calcium